首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1800212

全球癌症診斷市場 - 2025-2030 年預測

Global Cancer Diagnostics Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

癌症診斷市場預計將從 2025 年的 1,317.33 億美元成長到 2030 年的 1,827.85 億美元，複合年成長率為 6.77%。

癌症診斷市場涵蓋癌症檢測所需工具和技術的開發、生產和商業化，包括影像檢查（例如X光、電腦斷層掃描、MRI）、血液檢查、切片檢查以及分子診斷（例如腫瘤標記檢測）。該市場對醫療保健行業至關重要，因為早期準確的診斷能夠顯著改善患者的預後，從而實現及時治療。預計在2025年至2030年期間，受癌症發生率上升和技術進步的推動，該市場將經歷強勁成長。然而，高成本和發展中地區獲取管道有限等挑戰可能會阻礙市場擴張。

市場促進因素

癌症診斷市場的主要驅動力是全球癌症發生率的上升，這推動了對有效診斷工具的需求。癌症（尤其是乳癌）負擔的持續加重，凸顯了早期發現以提高治療成功率的必要性。政府支持也是一個關鍵因素，諸如加速創新診斷監管核准等舉措推動了市場成長。例如，監管機構越來越認知到液態切片等先進診斷技術在早期發現和改善患者預後的潛力。此外，產業參與者加大對研發的投資，推動了診斷解決方案的創新，從而進一步促進了市場的發展。

市場限制

癌症診斷市場面臨許多挑戰，例如先進診斷技術成本高昂、可近性有限，尤其是在資源匱乏的地區。此外，不同地區醫療基礎設施的差異也阻礙了先進診斷方法的廣泛應用。新興國家對篩檢計畫的認知度和可及性有限也構成了障礙，可能會延遲診斷並影響市場成長。透過經濟高效的解決方案來應對這些挑戰並擴大醫療保健的可近性，對於市場持續擴張至關重要。

介紹
北美洲
- 透過診斷程序
- 按癌症類型
- 按最終用戶
- 按國家
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 透過診斷程序
- 按癌症類型
- 按最終用戶
- 按國家
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 透過診斷程序
- 按癌症類型
- 按最終用戶
- 按國家
  - 德國
  - 法國
  - 英國
  - 西班牙
  - 其他
中東和非洲
- 透過診斷程序
- 按癌症類型
- 按最終用戶
- 按國家
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 以色列
  - 其他
亞太地區
- 透過診斷程序
- 按癌症類型
- 按最終用戶
- 按國家
  - 中國
  - 印度
  - 日本
  - 韓國
  - 印尼
  - 泰國
  - 台灣
  - 其他

第9章競爭格局及分析

主要企業和策略分析
市場佔有率分析
合併、收購、協議和合作
競爭對手儀表板

第10章：公司簡介

bioMerieux SA
Roche Diagnostics
MetaCell
Breath Diagnostics, Inc
Metabiomics
Castle Biosciences, Inc.
Exact Sciences Corporation
Thermo Fisher Scientific Inc.
Abbott Laboratories
GE Healthcare
Siemens Healthineers（Siemens AG）

第11章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要利益
調查方法
簡稱

簡介目錄

Product Code: KSI061611698

The global cancer diagnostics market is expected to grow from USD131.733 billion in 2025 to USD182.785 billion in 2030, at a CAGR of 6.77%.

The cancer diagnostics market encompasses the development, production, and commercialization of tools and technologies critical for detecting cancer, including imaging tests (e.g., X-rays, CT scans, MRI), blood tests, biopsies, and molecular diagnostics such as genetic and tumor marker tests. This market is vital to the healthcare industry, as early and accurate diagnosis significantly improves patient outcomes by enabling timely treatment. The market is projected to experience robust growth from 2025 to 2030, driven by rising cancer incidence and technological advancements. However, challenges such as high costs and limited access in developing regions may hinder progress.

Market Drivers

The primary driver of the cancer diagnostics market is the escalating global incidence of cancer, which increases the demand for effective diagnostic tools. The growing burden of cancer, particularly breast cancer, underscores the need for early detection to enhance treatment success rates. Government support is another key factor, with initiatives like expedited regulatory approvals for innovative diagnostics boosting market growth. For instance, regulatory bodies are increasingly recognizing the potential of advanced diagnostic technologies, such as liquid biopsies, to improve early detection and patient outcomes. Additionally, heightened investment in research and development by industry players is fostering innovation in diagnostic solutions, further propelling the market.

Market Restraints

The cancer diagnostics market faces challenges, including the high cost of advanced diagnostic technologies, which can limit accessibility, particularly in low-resource settings. Additionally, disparities in healthcare infrastructure across regions hinder the widespread adoption of sophisticated diagnostics. Limited awareness and access to screening programs in developing countries also pose barriers, potentially delaying diagnoses and impacting market growth. Addressing these challenges through cost-effective solutions and expanded healthcare access will be critical for sustained market expansion.

Market Segmentation

By Diagnostic Procedures

The cancer diagnostics market is segmented into laboratory tests, imaging procedures, and biopsies. Laboratory tests, including blood, urine, and genetic tests, are expected to hold a significant market share due to their versatility and increasing use in early detection. Imaging procedures, such as CT scans and MRIs, remain essential for visualizing tumors, while biopsies provide definitive diagnoses. The laboratory test segment is anticipated to grow steadily, driven by advancements in molecular diagnostics and tumor marker tests.

By Cancer Type

Breast cancer diagnostics represent a substantial market segment, driven by the disease's high prevalence among women globally. The surge in investment in breast cancer diagnostic tools, including advanced imaging and molecular tests, is expected to fuel growth in this segment. Other cancer types, such as lung and colorectal, also contribute to market demand, with diagnostics tailored to specific genetic and biomarker profiles gaining traction.

By Geography

The global cancer diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East and Africa. Asia-Pacific leads in cancer incidence due to its large population, driving significant demand for diagnostics. North America and Europe follow, with advanced healthcare systems and high adoption of cutting-edge technologies. In the United States, factors such as rising alcohol and tobacco consumption, sedentary lifestyles, and genetic predispositions contribute to market growth, with increasing cancer cases necessitating enhanced diagnostic and screening efforts. Emerging regions like South America and the Middle East and Africa are expected to grow as healthcare infrastructure improves.

Key Industry Players

Major players in the cancer diagnostics market include bioMerieux SA, F. Hoffmann-La Roche Ltd, Sienna Cancer Diagnostics, and Insight Medical Genetics. These companies are heavily investing in research and development to advance diagnostic technologies, such as next-generation sequencing and liquid biopsies, to meet growing demand and improve diagnostic accuracy.

The cancer diagnostics market is set for significant growth from 2025 to 2030, driven by rising cancer incidence, government support, and technological innovations. Despite challenges like high costs and limited access, the market's outlook remains positive, particularly in high-incidence regions like Asia-Pacific and advanced markets like North America. Industry players must focus on affordability and accessibility to fully capitalize on the growing demand for early and accurate cancer diagnostics.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Global Critical Care Diagnostics Market Segmentation

By Diagnostic Procedure

Laboratory Test
Imaging Procedures
Biopsy

By Cancer Type

Lung Cancer
Breast Cancer
Colorectal Cancer
Skin Cancer
Stomach Cancer
Others

By End-User

Hospitals
Clinics
Diagnostics Centers

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
South Korea
Taiwan
Indonesia
Japan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CANCER DIAGNOSTICS MARKET BY DIAGNOSTICS PROCEDURES

5.1. Introduction
5.2. Laboratory Test
5.3. Imaging Procedures
5.4. Bipsy

6. GLOBAL CANCER DIAGNOSTICS MARKET BY CANCER TYPE

6.1. Introduction
6.2. Lung cancer
6.3. Breast cancer
6.4. Colorectal Cancer
6.5. Skin Cancer
6.6. Stomach Cancer
6.7. Others

7. GLOBAL CANCER DIAGNOSTICS MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Diagnostics Centers

8. GLOBAL CANCER DIAGNOSTICS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Diagnostic Procedures
- 8.2.2. By Cancer Type
- 8.2.3. By End-User
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Diagnostic Procedures
- 8.3.2. By Cancer Type
- 8.3.3. By End-User
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Diagnostic Procedures
- 8.4.2. By Cancer Type
- 8.4.3. By End-User
- 8.4.4. By Country
  - 8.4.4.1. Germany
  - 8.4.4.2. France
  - 8.4.4.3. United Kingdom
  - 8.4.4.4. Spain
  - 8.4.4.5. Others
8.5. Middle East and Africa
- 8.5.1. By Diagnostic Procedures
- 8.5.2. By Cancer Type
- 8.5.3. By End-User
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Israel
  - 8.5.4.4. Others
8.6. Asia Pacific
- 8.6.1. By Diagnostic Procedures
- 8.6.2. By Cancer Type
- 8.6.3. By End-User
- 8.6.4. By Country
  - 8.6.4.1. China
  - 8.6.4.2. India
  - 8.6.4.3. Japan
  - 8.6.4.4. South Korea
  - 8.6.4.5. Indonesia
  - 8.6.4.6. Thailand
  - 8.6.4.7. Taiwan
  - 8.6.4.8. Others